<DOC>
	<DOCNO>NCT02565914</DOCNO>
	<brief_summary>This Phase 3 , multicenter , open-label , rollover study subject CF homozygous heterozygous F508del-CFTR mutation participate Studies 103 ( NCT02070744 ) , 106 ( NCT02347657 ) , 107 ( NCT02516410 ) , 108 ( NCT02392234 ) , 109 ( NCT02412111 ) , 111 ( NCT02508207 ) . The study design evaluate safety efficacy long term treatment VX-661 combination ivacaftor . This study consist Treatment Cohort Observational Cohort . The Treatment Cohort Observational Cohort open enrollment parallel .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Long Term Treatment With VX-661 Combination With Ivacaftor Subjects With Cystic Fibrosis Who Have F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects enter Treatment Cohort must meet following criterion : Elect enroll Treatment Cohort Completed study drug Treatment Period parent study ( Studies 103 [ Placebo Controlled Phase Open Label Extension Phase ] , 106 , 107 , 108 , 109 ) study drug treatment Safety Follow Visit subject Study 111 Willing remain stable CF regimen Safety Followup Visit . Subjects enter Observational Cohort must meet following criterion : &lt; 18 year age ( age date inform consent/assent parent study ) Completed study drug Treatment Period parent study study drug treatment Safety Follow Visit subject Study 111 , elect enroll Study 110 Treatment Cohort ; Received least 4 week study drug treatment complete visit last scheduled visit Treatment Period parent study ( Safety Follow Visit subject Study 111 ) , meet eligibility criterion enrollment Treatment Cohort History comorbidity , opinion investigator , might confound result study pose additional risk subject . Pregnant nursing female . Sexually active subject reproductive potential willing follow contraception requirement . History drug intolerance parent study would pose additional risk subject . Participation investigational drug trial ( include study investigate VX 661/ivacaftor lumacaftor/ivacaftor ) parent study 111 ( NCT02508207 ) use commercially available CFTR modulator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>